pipeline

ABL Bio is the first biotech company in Korea with a bispecific antibody platform that is undergoing clinical trial.

  • CNS Disease
    Bispecific antibody to penetrate BBB (Blood Brain Barrier) targeting insulin-like growth factor 1 receptor (IGF1R) as a BBB shuttle
    Developing Grabody-B platform for the treatment of various neurodegenerative diseases
  • IMMUNO-ONCOLOGY
    Bispecific antibody to address current limitations of PD-(L)1 checkpoint inhibitors
    Minimize systemic toxicity known to 4-1BB based immunotherapeutic, increase reponse rate and overcome resistance observed with PD-(L)1 therapy
  • ADC
    ADC showing a better
    therapeutic index
    Developing ADC with a better in vivo pharmacokinetic parameters for drug candidate to cure rare blood cancers.

MORE

INVESTOR RELATIONS

Information on ABL Bio's IR

career

ABL Bio History

ABL Bio

2022

  • 05

    Article about ABL501 published in Molecular Therapy

  • 03

    ABL111 received Orphan-Drug Designation

  • 01

    Signs licensing agreement with Sanofi

2021

  • 12

    re-certified as Korea Innovative Pharmaceutical Company

  • 08

    ABL501 Phase 1 clinical trial IND approved by MFDS

  • 07

    Review paper on bispecific antibody-based immunotherapy published in Vaccines

  • 06

    First patient dosed in Phase 1 clinical trial in of ABL111

  • 04

    First patient dosed in Phase 1 clinical trial of ABL503

  • 03

    ABL111 phase 1 clinical trial IND approved by U.S. FDA

  • 02

    ABL001 Phase 1 clinical trial IND approved by MFDS

  • 01

    ABL503 Phase 1 clinical trial IND approved by U.S. FDA

  • 01

    ABL's 4-1BB bispecific antibody introduced in 'Science Advances'

  • 01

    ABL001 research published in International Journal of Molecular Sciences

MORE